Continued Optimism for Alnylam Pharmaceuticals' (ALNY) Apollo-B Success - Oppenheimer
Tweet Send to a Friend
Oppenheimer analyst Leland Gershell reiterated an Outperform rating and $200.00 price target on Alnylam Pharmaceuticals (NASDAQ: ALNY), following a recent ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
